Display options
Cite
Dumonceau RG, Soeiro T, Lacroix C, et al. Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12738.
Dumonceau, R. G., Soeiro, T., Lacroix, C., Giocanti, A., Frauger, �. �., Mezaache, S., & Micallef, J. (2021). Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12738
Dumonceau, Robinson Gravier, et al. "Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12738
Dumonceau RG, Soeiro T, Lacroix C, Giocanti A, Frauger É, Mezaache S, Micallef J. Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundam Clin Pharmacol. 2021 Nov 27; doi: 10.1111/fcp.12738. Epub 2021 Nov 27. PMID: 34837277.
Copy Download .nbib Format: NLM
Share it on

Fundam Clin Pharmacol. 2021 Nov 27; doi: 10.1111/fcp.12738. Epub 2021 Nov 27.

Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program.

Fundamental & clinical pharmacology

Robinson Gravier Dumonceau, Thomas Soeiro, Clémence Lacroix, Adeline Giocanti, Élisabeth Frauger, Salim Mezaache, Joëlle Micallef

Affiliations

  1. Assistance publique - Hôpitaux de Marseille, Service de pharmacologie clinique, Centre d'Évaluation et d'information sur la pharmacodépendance - Addictovigilance PACA Corse, Marseille, France.
  2. Aix-Marseille Université, Inserm, UMR 1106, Marseille, France.

PMID: 34837277 DOI: 10.1111/fcp.12738

Abstract

Accumulating evidence shows that some antidepressants are abused for their psychostimulant effects, but the extent of antidepressants abuse is unknown in subjects with opioid use disorders (OUD). The objective of this work is to assess the prevalence of antidepressant abuse and its correlates in subjects with OUD. Subjects ≥18 year-old in an opiate maintenance treatment (OMT) program who reported using an antidepressant were selected from the OPPIDUM program from 2011 to 2020. The outcome was antidepressant abuse. Antidepressant abusers were identified as subjects reporting at least one of the following behaviors: "drug abuse," "concomitant use of alcohol," "illegal obtaining," and "dose higher than recommended in the Summary of Product Characteristics." Among the 83 040 observations of subjects ≥18 year-old in an OMT program included in the OPPIDUM program from 2011 to 2020, 2708 (3.3%) subjects reported using an antidepressant in monotherapy. Among them, there were 385 (14.2%) abusers. The proportion of abusers was the highest for amitriptyline (n = 31, 25.0%). In multivariate analysis, antidepressant abuse was positively associated with amitriptyline (OR 2.07, 95% CI [1.16, 3.73]; p = 0.015), unemployment (OR 1.52, 95% CI [1.16, 2.01]; p = 0.003), the use of intravenous route of administration (OR 1.77, 95% CI [1.12, 2.80]; p = 0.014), and the use of benzodiazepines (OR 1.53, 95% CI [1.21, 1.94]; p < 0.001). Clinicians should be aware of the risk of antidepressant abuse when prescribing in subjects with OUD, accounting for their heterogeneous pharmacological properties that may account for their abuse potential.

© 2021 Société Française de Pharmacologie et de Thérapeutique.

Keywords: addictovigilance; antidepressants; opiate maintenance treatment; opioid use disorders; postmarketing surveillance; prescription drug abuse

References

  1. Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther. 2010;88(3):307-317. - PubMed
  2. Sullivan M, Evans E. Abuse and misuse of antidepressants. SAR. 2014;5:107. - PubMed
  3. Rushton W, Whitworth B, Brown J, Kurz M, Rivera J. Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health. Clin Toxicol. 2021;59(2):152-157. - PubMed
  4. Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse-proactive pharmacovigilance. N Engl J Med. 2018;379(3):205-207. - PubMed
  5. Jouanjus E, Gibaja V, Kahn J-P, Haramburu F, Daveluy A. Signal identification in addictovigilance: the functioning of the French system. Therapies. 2015;70(2):123-131. - PubMed
  6. Lapeyre-Mestre M, Boucher A, Daveluy A, et al. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapies. 2020;75(4):343-354. - PubMed
  7. Micallef J, Frauger E, Palmaro A, Boucherie Q, Mestre ML. Example of an investigation of an “emergent” phenomenon in addiction vigilance: the case of methylphenidate. Therapies. 2015;70(2):197-202. - PubMed
  8. Tambon M, Ponté C, Jouanjus E, et al. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psych. 2021;3(12):639780. - PubMed
  9. Frauger E, Moracchini C, Le Boisselier R, et al. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol. 2013;27(6):672-682. - PubMed
  10. Frauger E, Nordmann S, Orleans V, et al. Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey: which psychoactive prescription drugs are illegally obtained? Fundam Clin Pharmacol. 2012;26(4):549-556. - PubMed
  11. Daveluy A, Frauger E, Peyrière H, Moracchini C, Haramburu F, Micallef J. Which psychoactive substances are used by patients seen in the healthcare system in French overseas territories? Results of the OPPIDUM survey. Fundam Clin Pharmacol. 2017;31(1):126-131. - PubMed
  12. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse. 1995;7(4):481-497. - PubMed
  13. Ahmadi J, Majdi B, Mahdavi S, Mohagheghzadeh M. Mood disorders in opioid-dependent patients. J Affect Disord. 2004;82(1):139-142. - PubMed
  14. Hunt GE, Malhi GS, Lai HMX, Cleary M. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: systematic review and meta-analysis. J Affect Disord. 2020;266:288-304. - PubMed
  15. Lin LA, Bohnert ASB, Blow FC, et al. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction. 2021;116(1):96-104. - PubMed
  16. Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244-250. - PubMed
  17. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2021. https://www.R-project.org - PubMed
  18. Wickham H. ggplot2: Elegant Graphics for Data Analysis. 2nded. Cham: Springer International Publishing; 2016 Imprint: Springer; 2016. 1 p. (Use R!). - PubMed
  19. Castot A, Benzaken C, Wagniart F, Efthymiou ML. Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance. Therapie. 1990;45(5):399-405. - PubMed
  20. Rouby F, Pradel V, Frauger E, et al. Assessment of abuse of tianeptine from a reimbursement database using ‘doctor-shopping’ as an indicator: assessment of abuse liability of tianeptine. Fundam Clin Pharmacol. 2012;26(2):286-294. - PubMed
  21. Lauhan R, Hsu A, Alam A, Beizai K. Tianeptine abuse and dependence: case report and literature review. Psychosomatics. 2018;59(6):547-553. - PubMed
  22. Cohen MJ. Abuse of amitriptyline. Jama. 1978;240(13):1372-1373. - PubMed
  23. Peles E, Schreiber S, Adelson M. Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT). Eur Neuropsychopharmacol. 2008;18(3):188-193. - PubMed
  24. Iliou T, Casta P, Lequeux J, et al. Venlafaxine abuse in a patient with a history of methylphenidate abuse: a case report. J Clin Psychopharmacol. 2019;39(2):172-174. - PubMed
  25. Di Matteo V, Di Mascio M, Di Giovanni G, Esposito E. Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin 2C receptors. Psychopharmacology (Berl). 2000;150(1):45-51. - PubMed
  26. Gassaway MM, Rives M-L, Kruegel AC, Javitch JA, Sames D. The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Transl Psychiatry. 2014;4(7):e411. - PubMed
  27. Olianas MC, Dedoni S, Onali P. The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors: mianserin agonism at κ-opioid receptors. Br J Pharmacol. 2012;167(6):1329-1341. - PubMed
  28. Saad MH, Savonen CL, Rumschlag M, Todi SV, Schmidt CJ, Bannon MJ. Opioid deaths: trends, biomarkers, and potential drug interactions revealed by decision tree analyses. Front Neurosci. 2018;12:728. - PubMed
  29. Frauger E, Fouilhé Sam-Laï N, Mallaret M, Micallef J. Améliorer la balance bénéfices/risques de la méthadone en respectant ses spécificités pharmacologiques. Therapies. 2019;74(3):383-388. - PubMed
  30. Compton WM, Gfroerer J, Conway KP, Finger MS. Unemployment and substance outcomes in the United States 2002-2010. Drug Alcohol Depend. 2014;142:350-353. - PubMed
  31. Azagba S, Shan L, Qeadan F, Wolfson M. Unemployment rate, opioids misuse and other substance abuse: quasi-experimental evidence from treatment admissions data. BMC Psychiatry. 2021;21(1):22. - PubMed
  32. Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M. Assessment of abuse potential of benzodiazepines from a prescription database using ‘doctor shopping’ as an indicator. CNS Drugs. 2010;24(7):611-620. - PubMed
  33. Darke S, Hall W. Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend. 1995;39(3):231-235. - PubMed

Publication Types